Liposomal Bupivacaine and Novel Local Anesthetic Formulations

Publication date: Available online 19 July 2019Source: Best Practice & Research Clinical AnaesthesiologyAuthor(s): Amit Prabhakar, Ceressa T. Ward, Matthew Watson, Jay Sanford, Babar Fiza, Vanessa Moll, Rachel J. Kaye, O. Morgan Hall, Elyse M. Cornett, Richard D. Urman, Alan David KayeAbstractNovel preparations allowing for extending duration of action of local anesthetics have many clinically relevant benefits. In this regard, the development of liposomal bupivacaine has the potential to significantly impact patient care by improving perioperative pain control. The unique liposomal bilayer that encapsulates bupivacaine allows for a sustained release of local anesthetic for up to 72 hours after a single use and can significantly decrease post-operative opioid consumption. SABER-bupivacaine is another depot formulation that is a sustained release of bupivacaine of encapsulated bupivacaine in a biodegradeable sucrose acetate isobutyrate biolayer. HTX-011 is an investigational extended release local anesthetic formulation currently undergoing Phase 3 clinical trials. HTX-011 is composed of a bioerodible polymer with bupivacaine and low dose meloxicam in which the polymer undergoes hydrolysis and allows for sustained release of bupivacaine and meloxicam over 3 days. The present investigation reviews pharmacologic considerations related to the formulation of liposomal bupivacaine, current FDA approved indications for its use, and future extended release local anesthetic formulatio...

Source: Best Practice and Research Clinical Anaesthesiology - July 20, 2019 Category: Anesthesiology Source Type: research